News Roche poised to buy MASH drug developer 89bio for $3.5bn Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its phase 3 candidate pegozafermin for MASH.
News Novo Nordisk claims first GLP-1 approval in MASH Under pressure from rivals in the GLP-1 space, Novo Nordisk has been given a leg-up with a first-in-class approval for Wegovy in liver disease MASH.
News Madrigal closes on EU approval of first MASH treatment Madrigal Pharma could be just weeks away from becoming the first drugmaker to claim EU approval for a MASH treatment.
News GSK pays $1.2bn for liver drug as it culls TIGIT programme GSK decided to abandon a TIGIT-targeted drug for cancer this week, then hatched a plan to replace it with a candidate for liver disease MASH.
R&D Navigating the complexities of drug development in hepatolog... In the realm of medical research, liver disease remains a complex and often overlooked field.
News Fabhalta is first FDA-approved therapy for rare disease C3G Novartis' oral complement inhibitor Fabhalta has become the first approved treatment for rare kidney disease C3G as it chases a $3bn sales target.
Digital FH25: Jessica DaMassa on hosting, hype, and health innovatio... In a new episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with WTF Health founder and event emcee, Jessica DaMassa
Digital Sponsored Tracking studies get smarter: AI meets human intelligence Having a continuous pulse on brand health is essential for pharmaceutical companies to inform strategic decisions and establish Key Performance Indicators (KPIs) in an ever-changing market